Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Objectives Previous studies have investigated the occupancy of the serotonin reuptake transporter (SERT) after clinical doses of citalopram and other selective serotonin reuptake inhibitors. In the present study, the occupancies of SERT after multiple doses of escitalopram and citalopram were compared using the radioligand [(123)I]ADAM and single photon emission computed tomography (SPECT).Methods Fifteen healthy subjects received escitalopram 10 mg/day (n = 6) or citalopram 20 mg/day (n = 9) for a total of 10 days. SERT occupancies in midbrain were determined with SPECT and [(123)I]ADAM at three different time points: at baseline (no medication) and at 6 and 54 h after last drug intake.Results At 6 h after the last dose, mean SERT occupancies were 81.5 +/- 5.4% (mean+/-SD) for escitalopram and 64.0 +/- 12.7% for citalopram (p < 0.01). At 54 h after the last dose, mean SERT occupancies were 63.3 +/- 12.1% for escitalopram and 49.0 +/- 11.7% for citalopram (p < 0.05). The plasma concentrations of the S-enantiomer were of the same magnitude in both substances. For both drugs, the elimination rate of the S-enantiomer in plasma was markedly higher than the occupancy decline rate in the midbrain.Conclusion The significantly higher occupancy of SERT after multiple doses of escitalopram compared to citalopram indicates an increased inhibition of SERT by escitalopram. The results can also be explained by an attenuating effect of R-citalopram on the occupancy of S-citalopram at the SERT.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For escitalopram [30], citalopram [36], and sertraline [30], but not paroxetine [30] and fluvoxamine [39], SERT occupancy appeared to decrease at a slower rate than the plasma concentration (Fig. 2).”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [36]
In the citing paper
“Five studies provided data on the time-course of SERT occupancy as it decreases over time after a single dose [30, 35, 39, 40] or repeated (7–10 days) [36, 40] administration of antidepressants in healthy volunteers.”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [36]
In the citing paper
“Three of these studies compared the decline rates of occupancy and plasma concentration (Fig. 2) [30, 36, 39].”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [36]
Citations
Cites
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705 · cited 2×
“All adverse events were rated as “mild” according to the UKU scale (Lingjaerde et al. 1987).”
BackgroundMethodMeyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517 · cited 5×
“First, Meyer et al. (2004) administered higher doses of citalopram (20 mg up to 60 mg) for a longer duration (10 vs 28 days) than we did.”
BackgroundMethodInfluentialBauer, M., Whybrow, P. C., Angst, J., Versiani, M., Möller, H.-J., & WFSBP Task Force on Treatment Guide (2002) · The World Journal of Biological Psychiatry · doi:10.3109/15622970209150599 · Cited by 346
Meyer, J. H., Wilson, A. A., Ginovart, N., Goulding, V., Hussey, D., Hood, K., & Houle, S. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1843 · Cited by 340
Escitalopram versus citalopram: the surprising role of the R-enantiomer
S�nchez, C., B�ges�, K., Ebert, B., Reines, E., & Braestrup, C. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1865-z · Cited by 248
Moore, N., Verdoux, H., & Fantino, B. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200505000-00002 · Cited by 188
Regional distribution of serotonin transporter protein in postmortem human brain
Kish, S. J., Furukawa, Y., Chang, L.-J., Tong, J., Ginovart, N., Wilson, A., Houle, S., & Meyer, J. H. (2005) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2004.10.001 · Cited by 179
Mørk, A., Kreilgaard, M., & Sánchez, C. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00138-2 · Cited by 163
High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue
Ba¨ckstro¨m, I., Bergstro¨m, M., & Marcusson, J. (1989) · Brain Research · doi:10.1016/0006-8993(89)90511-8 · Cited by 162
Oya, S., Choi, S.-R., Hou, C., Mu, M., Kung, M.-P., Acton, P. D., Siciliano, M., & Kung, H. F. (2000) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(00)00084-6 · Cited by 158
Significant dissociation of brain and plasma kinetics with antipsychotics
Tauscher, J. T., Jones, C. E., Remington, G. J., Zipursky, R. B., & Kapur, S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001009 · Cited by 155
Self-citationSøgaard, B., Mengel, H., Rao, N., & Larsen, F. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005280860 · Cited by 134
Murdoch, D. R., & Keam, S. J. (2005) · Drugs · doi:10.2165/00003495-200565160-00013 · Cited by 117
Noble, S., & Benfield, P. (1997) · CNS Drugs · doi:10.2165/00023210-199708050-00009 · Cited by 86
Colonna, L., Andersen, H. F., & Reines, E. H. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x65484 · Cited by 82
Klein, N., Sacher, J., Geiss-Granadia, T., Attarbaschi, T., Mossaheb, N., Lanzenberger, R., Pötzi, C., Holik, A., Spindelegger, C., Asenbaum, S., et al. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0486-0 · Cited by 77 · cited 8×
“[123I]ADAM was synthesized at MAP Medical Technologies Oy, Tikkakoski, Finland, as previously described (Oya et al. 2000) and purified with a high-performance liquid chromatography (HPLC) system as described by Klein et al. (2006).”
BackgroundMethodResultInfluentialSelf-citationGutierrez, M. M., Rosenberg, J. M., & Abramowitz, W. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80076-0 · Cited by 64
Herold, N., Uebelhack, K., Franke, L., Amthauer, H., Luedemann, L., Bruhn, H., Felix, R., Uebelhack, R., & Plotkin, M. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-005-0429-7 · Cited by 61
Time Course of In Vivo 5-HTT Transporter Occupancy by Fluvoxamine
Takano, A., Suhara, T., Ichimiya, T., Yasuno, F., & Suzuki, K. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000203201.34323.d3 · Cited by 25
Lack of Citalopram Effect on Oral Digoxin Pharmacokinetics
Larsen, F., Priskorn, M., & Overø, K. F. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010041 · Cited by 24
Pharmacokinetic Consequences of a Citalopram Treatment Discontinuation
Voirol, P., Rubin, C., Bryois, C., Kosel, M., Buclin, T., & Baumann, P. (1999) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199906000-00001 · Cited by 11
Unique mechanism of action for escitalopram: does it hold the promise?
Kasper, S. F. (2004) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500410005504 · Cited by 7
Self-citation
Research works printed but not linked: 1
- Baumann P, Larsen F (1995) The pharmacokinetics of citalopram. Rev Contemp Pharmacother 6:287–295
Cited by
The serotonin transporter in psychiatric disorders: insights from PET imaging
Spies, M., Knudsen, G. M., Lanzenberger, R., & Kasper, S. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00232-1 · Cited by 177
Self-citation5‐HT radioligands for human brain imaging with PET and SPECT
Paterson, L. M., Kornum, B. R., Nutt, D. J., Pike, V. W., & Knudsen, G. M. (2013) · Medicinal Research Reviews · doi:10.1002/med.20245 · Cited by 151
Lanzenberger, R., Kranz, G. S., Haeusler, D., Akimova, E., Savli, M., Hahn, A., Mitterhauser, M., Spindelegger, C., Philippe, C., Fink, M., et al. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.07.023 · Cited by 139
“Following the PET and SPECT studies stated above, our second aim was to investigate SERT binding and SERT occupancy (acute and subchronic) in relation to treatment outcome.”
MethodInfluentialSelf-citationSouery, D., Serretti, A., Calati, R., Oswald, P., Massat, I., Konstantinidis, A., Linotte, S., Bollen, J., Demyttenaere, K., Kasper, S., et al. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182228619 · Cited by 119
Self-citationWindischberger, C., Lanzenberger, R., Holik, A., Spindelegger, C., Stein, P., Moser, U., Gerstl, F., Fink, M., Moser, E., & Kasper, S. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2009.10.013 · Cited by 114
Self-citation
Metadata
- Authors
- Klein, N., Sacher, J., Geiss-Granadia, T., Mossaheb, N., Attarbaschi, T., Lanzenberger, R., Spindelegger, C., Holik, A., Asenbaum, S., Dudczak, R., Tauscher, J., & Kasper, S.
- Affiliations
- Medical University of Vienna (AT)
- Corresponding author
- Kasper, Siegfried
- Venue
- Psychopharmacology
- Published
- 2007-01-19
- Volume
- 191
- Issue
- 2
- Pages
- 333-339
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2033309297
- Cited by
- 62
- References
- 22
- Citations by year
- 2025: 1 · 2024: 1 · 2022: 4 · 2021: 3 · 2020: 4 · 2017: 2 · 2016: 5 · 2015: 3 · 2014: 4 · 2013: 2 · 2012: 5
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Max Planck Digital Library (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Eli Lilly and Company
- H. Lundbeck A/S
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- escitalopram, citalopram, selective serotonin reuptake inhibitors, repeated dosing, midbrain, drug elimination
- MeSH terms
- Adult, Brain, Cerebellum, Cinanserin, Dose-Response Relationship, Drug, Drug Administration Schedule, Humans, Male, Mesencephalon, Stereoisomerism, Time Factors, Tissue Distribution, Citalopram, Tomography, Emission-Computed, Single-Photon, Selective Serotonin Reuptake Inhibitors, Radiopharmaceuticals, Area Under Curve, Serotonin Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.